HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Seyed Isaac Hashemy Selected Research

Aprepitant (Emend)

6/2022The substance P/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells.
2/2022Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
1/2022The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification.
1/2022SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
4/2021Pathogenic role of the SP/ NK1R system in GBM cells through inhibiting the thioredoxin system.
1/2021Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-κB Signal Transduction Pathways in Colon Cancer Cells.
1/2021The SP/NK1R System-Mediated ROS Generation in GBM Cells through Inhibiting Glutaredoxin Protein.
1/2021Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-κB Axis in Cancer Stem-Like Esophageal Squamous Cell Carcinoma Spheres.
6/2020Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Seyed Isaac Hashemy Research Topics

Disease

30Neoplasms (Cancer)
06/2022 - 04/2006
7Neoplasm Metastasis (Metastasis)
06/2022 - 01/2018
5Colorectal Neoplasms (Colorectal Cancer)
06/2022 - 02/2018
4Carcinogenesis
01/2022 - 02/2019
4Glioblastoma (Glioblastoma Multiforme)
01/2022 - 01/2021
3Esophageal Squamous Cell Carcinoma
01/2021 - 03/2020
3Oral Lichen Planus
12/2020 - 01/2016
3Obesity
12/2019 - 06/2019
3Ovarian Neoplasms (Ovarian Cancer)
08/2019 - 01/2017
2Uterine Cervical Neoplasms (Cancer of the Cervix)
02/2022 - 11/2018
2Inflammation (Inflammations)
01/2022 - 12/2019
2Prostatic Neoplasms (Prostate Cancer)
01/2022 - 10/2021
2Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
09/2021 - 01/2019
2Colonic Neoplasms (Colon Cancer)
01/2021 - 02/2019
2Breast Neoplasms (Breast Cancer)
10/2020 - 02/2019
2Rheumatoid Arthritis
07/2020 - 01/2019
2Infections
01/2019 - 11/2018
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/2021
1Hodgkin Disease (Hodgkin's Disease)
09/2021
1Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2021
1Hematologic Neoplasms (Hematological Malignancy)
09/2021
1Non-alcoholic Fatty Liver Disease
03/2021
1Fibrosis (Cirrhosis)
03/2021
1Brain Neoplasms (Brain Tumor)
01/2021
1Nausea
01/2021
1Vomiting
01/2021
1Sepsis (Septicemia)
12/2020
1Squamous Cell Carcinoma of Head and Neck
12/2020
1Hypoxia (Hypoxemia)
10/2020
1Esophageal Neoplasms (Esophageal Cancer)
06/2020
1Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
06/2020
1Pruritus (Itching)
02/2020
1Chronic Urticaria
02/2020
1Psoriasis (Pustulosis Palmaris et Plantaris)
01/2020
1Cutaneous Leishmaniasis
12/2019
1Leishmaniasis
12/2019

Drug/Important Bio-Agent (IBA)

16Substance PIBA
06/2022 - 12/2018
12Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA
06/2022 - 12/2018
9Aprepitant (Emend)FDA Link
06/2022 - 06/2020
8MicroRNAs (MicroRNA)IBA
10/2021 - 02/2018
5NeuropeptidesIBA
02/2022 - 06/2020
5AntioxidantsIBA
01/2022 - 01/2018
4resazurinIBA
06/2022 - 01/2021
4Proteins (Proteins, Gene)FDA Link
01/2022 - 01/2019
4Immune Checkpoint InhibitorsIBA
09/2021 - 02/2019
4LeptinIBA
08/2019 - 01/2017
4Reactive Oxygen Species (Oxygen Radicals)IBA
01/2019 - 04/2006
3Therapeutic UsesIBA
02/2022 - 09/2021
3C-Reactive ProteinIBA
03/2021 - 01/2016
3Biomarkers (Surrogate Marker)IBA
07/2020 - 02/2018
3Thioredoxin-Disulfide ReductaseIBA
01/2020 - 04/2006
3Oxidants (Oxidizing Agents)IBA
12/2019 - 11/2016
2CytokinesIBA
10/2021 - 01/2020
2Peptides (Polypeptides)IBA
01/2021 - 03/2020
2TachykininsIBA
01/2021 - 06/2020
2Pharmaceutical PreparationsIBA
01/2021 - 04/2006
2ThioredoxinsIBA
12/2020 - 11/2019
2Immune Checkpoint ProteinsIBA
10/2020 - 10/2019
2LigandsIBA
01/2020 - 10/2019
2AdipokinesIBA
12/2019 - 01/2018
2IsoprostanesIBA
12/2019 - 03/2016
2Hormones (Hormone)IBA
06/2019 - 01/2017
2Monoclonal AntibodiesIBA
02/2019 - 01/2019
1GelatinIBA
06/2022
1Protein Isoforms (Isoforms)IBA
01/2022
1LipopolysaccharidesIBA
01/2022
1AcidsIBA
01/2022
1Cyclin B1IBA
01/2022
1Cyclin D1IBA
01/2022
1AndrogensIBA
10/2021
1Androgen Receptors (Androgen Receptor)IBA
10/2021
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
10/2021
1Anti-Inflammatory Agents (Anti-Inflammatories)IBA
03/2021
1Propolis (Bee Bread)IBA
03/2021
1Superoxide DismutaseIBA
01/2021
1Antineoplastic Agents (Antineoplastics)IBA
01/2021
1CatalaseIBA
01/2021
1Annexin A5IBA
01/2021
1CaspasesIBA
01/2021
1Acetylcysteine (Siran)FDA LinkGeneric
12/2020
1Cysteine (L-Cysteine)FDA Link
12/2020
1InterferonsIBA
10/2020
1B7-H1 AntigenIBA
10/2020
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
10/2020
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
10/2020
1cyclic citrullinated peptideIBA
07/2020
1Tachykinin Receptors (Tachykinin Receptor)IBA
06/2020
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
06/2020
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2020
1FluoroquinolonesIBA
06/2020
1Anti-Bacterial Agents (Antibiotics)IBA
06/2020
1Neurotransmitter Agents (Neurotransmitter)IBA
02/2020
1AntibodiesIBA
10/2019
1CTLA-4 AntigenIBA
10/2019
1Estrogens (Estrogen)FDA Link
08/2019

Therapy/Procedure

12Therapeutics
01/2022 - 11/2018
6Drug Therapy (Chemotherapy)
01/2021 - 01/2019
4Immunotherapy
09/2021 - 10/2019
2Radiotherapy
01/2021 - 04/2019
1Castration
10/2021